High-Dose Vitamin C for Cancer Patients with Refractory Non-Hodgkin Lymphoma (NHL)

Thomas Jefferson University is enrolling people with Non-Hodgkin Lymphoma to participate in a research study to assess the effects of high-dose, intravenous vitamin C on disease progression and quality of life in patients who have failed standard therapies.

Eligible participants will receive approximately three infusions per week for ten weeks.

Vitamin C infusions will be administered free of charge.

Participants must:

• Have diagnosis of Non-Hodgkin Lymphoma
• Have been treated with one or more standard cancer treatments
• Be refractory to standard treatment or ineligible for additional standard treatment, as determined by study oncologist
• Be able to receive infusions 3 times per week for 10 weeks

 

If you are interested in participating in the study or getting more information, call Dr. Edman (study coordinator) at 215-955-2839 or email Joel.Edman@jefferson.edu.

This study is a joint effort between with Myrna Brind Center of Integrative Medicine and the Kimmel Cancer Center.

Primary investigators are Daniel Monti, MD (Principle Investigator), and Joanne Filicko, MD (study oncologist).

Download Detailed Study PDF>>